This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Buoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based shot for seasonal influenza, targeting four different flu strains. . The first patents have now been enrolled into the study of the shot – codenamed mRNA-1010 – which is designed to generate antibodies against influenza A H1N1, H3N2 and influenza B Yamagata and Victoria – all of which are recommended by the World Health Organization (WHO).
The immunotherapy firm is conducting a Phase III trial centered on an innovative approach to treating recurrent glioblastoma, an aggressive brain cancer.
At this year’s Pharma USA conference, C ollaboration was the theme of the opening keynote session and a common thread woven throughout the event as industry leaders gathered to discuss how to move “Beyond Normal” to shape the future of health. In her opening statement, Izzy Gladstone, Reuters’ Head of Marketing, Pharma & Healthcare, challenged attendees to not return to our old ways of working.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The UK’s biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – which is a record for the industry. The new figures – from the BioIndustry Association and Clarivate – were dominated by more than £1 billion in venture capital funding for UK biotech and life sciences companies, headlined by DNA sequencing company Oxford Nanopore’s £195 million raise in May that was just shy of the £205 million re
During the Rare/Orphan Diseases, Special Patient Population webinar, a group of industry experts discussed challenges and opportunities faced in the field.
Pharmacists from your community pharmacy in Kentucky are the most approachable healthcare professionals you can talk to. As medication experts you can trust, they can answer your questions regarding your care plan, medications, and disease management. This may include explaining how to take your medication or providing more information about a disease to enhance your health.
A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. The interim readout from the 39-patient HERIZON trial found 50% of patients treated with the HER-Vaxx (IMU-131) vaccine on top of chemotherapy achieved a partial response or better, compared to 29% of patients given only chemo.
A leader from IQVIA suggests what to look for when seeking ways to automate drug safety processes, while maintaining security and customer satisfaction.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Testosterone is an essential hormone and steroid that affects many physiological functions. It is naturally more prevalent as an androgynous hormone in men, and it is therefore much more essential for them to have adequate amounts of it. However, with age, levels of this primary hormone can take a dive, usually for the worse. Symptoms of low testosterone may include weight gain, anxiety, low energy levels, low libido, insomnia, loss of concentration, and low mood.
Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. Millions of tests for COVID-19 are taken worldwide every day, as they become an increasingly important tool for our return to normality. Testing programmes have been rolled out by governments globally with the important purpose of tracking the spread of the SARS-CoV-2 virus and letting individuals know whe
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Join the Society for Health Care Strategy and Market Development (SHSMD) at their annual conference, SHSMD Connections 2021 this autumn. This annual conference is beneficial for health care strategists at any stage in their career that want to connect and learn from other industry professionals. Participants come from across the nation and possess a wide range of expertise about various facets of the health care strategy sector.
Orchard Therapeutics’ gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use by NICE in draft guidance. The agency said that while there was evidence of a short-term benefit with Libmeldy (atidarsagene autotemcel or OTL-200 ), assumptions about its long-term effects are uncertain, making it unclear whether it will offer value for money to the NHS.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
In this article, we’d like to share some of the most common dextromethorphan clinical pearls that you should be aware of. Dextromethorphan (DXM) is an over-the-counter medication often found in many of the Robitussin products, among others. It is approved to treat cough in adults and children 12 and older. Relief starts 15-30 minutes after […].
GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. . Hoos is leaving GSK after nine years, a period that saw a complete revamp of the unit including the wholesale divestment of cancer drugs to Novartis in a $16 billion deal announced in 2014 – which completed as he took over the division.
This monthâs news on hires, promotions, acquisitions, and expansions includes items about Javara, Elligo, Lonza, Yourway, Medable, and other notable firms.
FAIRFIELD, NJ, 30 June, 2021- The Healthcare Businesswomen’s Association Board of Directors announces the appointment of Susan O’Connor as Chief Executive Officer of the global not-for-profit association, ushering in a new chapter in its mission of advancing women in healthcare. Ms. O’Connor will succeed current President and CEO Laurie Cooke, who will step down for a well-earned retirement after leading the organization since 2006.
The Israeli Ministry of Health has reported data suggesting that the efficacy of the Pfizer/BioNTech COVID-19 vaccine has become less effective at preventing the spread of the coronavirus after the emergence of the delta variant. The vaccine still seems to be able to prevent hospitalisation and severe cases of COVID-19, but its efficacy in preventing symptomatic infections seems to have fallen from a high of 94% at the start of the rollout to 64% now, which it attributes to the emergence of the
The two organizations have joined to create the Advocacy Exchange, a virtual platform designed to bring together patients, advocates and industry leader.
Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug. The US regulator issued Novartis with a complete response letter (CRL) for inclisiran in December, citing “unresolved facility inspection-related conditions” at a third-party manufacturing site run by Corden Pharma near Milan, Italy.
Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. To-date, the battle against COVID-19 has been waged largely in the field of public health, using a series of binary, black-and-white thresholds to measure progress. The number of positive cases per 100,000 people, yes/no results on PCR tests, absence or presence of antibodies – these have set the benchmarks used to determine when we can open our schools and restaurants, remove our masks and resume some
With the COVID-19 delta variant has become the dominant strain circulating in the US, Pfizer and BioNTech have said they will ask the FDA and other regulators to approve a third dose of their Comirnaty vaccine to guard against a winter surge in cases. . The two companies have revealed data from an ongoing trial of the booster Comirnaty (BNT162b2) jab, saying that a dose given six months after the second dose stimulates a strong antibody response against both the original wild type and the worris
The FDA indicated something was not well with Provention Bio’s filing for type 1 diabetes therapy teplizumab in April when it delayed its review. Now, the agency has rejected the application entirely, sending the company’s shares into a steep slide. The complete response letter (CRL) for teplizumab as a treatment to delay clinical type 1 diabetes in at-risk individuals reiterates the FDA’s concerns around the pharmacokinetics (PK) data for the antibody.
The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the UK as the last remaining obstacle to getting the deal across the line. The EU approval comes after the merger has already been okayed by the US, Japan and a number of other countries around the world, and AZ says it is now hoping to completing the transaction by the end of this quarter.
UK-based online marketing agency Performance.io (PIO) has appointed Jason Brown as it’s global chief commercial officer. Brown has held several senior leadership positions at pharma companies including Sanofi and Novartis, before joining sales force benchmarking organisation, STEM where he was promoted to President of EU5 and global COO. His most recent role was as chief commercial officer at Pharmaspectra, where he was responsible for the company’s international growth.
As demonstrated throughout COVID, digital health is no longer experimental. Digital technologies are proving their value by allowing for better care, improved adherence and a more connected ecosystem between doctors, patients and pharma. Ampersand Health has been working in the space since 2015 and has seen it evolve from a niche approach with limited acceptance to widespread acceptance and deployment across disease areas in a matter of years.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
145 
Let's personalize your content